Christine Poon - Koninklijke Philips Chairman
| PHG Stock | USD 26.05 0.21 0.80% |
Chairman
Ms. Christine A. Poon was Independent Vice Chairman of the Supervisory Board and Secretary of Koninklijke Philips N.V. since 2014. Prior to that, she was Member of the Supervisory Board of the Company from March 27, 2009. She is former Vice Chairman of Johnson Johnson Board of Directors and Worldwide Chairman of the Pharmaceuticals Group. She is former Dean of Ohio State University Fisher College of Business. She is Member of the Board of Directors of Prudential and Regeneron. She is a graduate of Northwestern University with a Bachelor of Arts degree in Biology in 1973, she acquired an MS degree in Biology and Biochemistry at St. Louis University in 1976 and an Master Business Administration in Finance from Boston University in 1982. She is Member of the Remuneration Committee, the Quality and Regulatory Committee and the Corporationrationrate Governance and Nomination Selection Committee. since 2014.
| Age | 67 |
| Tenure | 10 years |
| Address | Philips Center, Amsterdam, Netherlands, 1096 BC |
| Phone | 31 20 597 7777 |
| Web | https://www.philips.com |
Christine Poon Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christine Poon against Koninklijke Philips stock is an integral part of due diligence when investing in Koninklijke Philips. Christine Poon insider activity provides valuable insight into whether Koninklijke Philips is net buyers or sellers over its current business cycle. Note, Koninklijke Philips insiders must abide by specific rules, including filing SEC forms every time they buy or sell Koninklijke Philips'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christine Poon over a month ago Acquisition by Christine Poon of 1840 shares of Prudential Financial subject to Rule 16b-3 | ||
Christine Poon over two months ago Acquisition by Christine Poon of tradable shares of Prudential Financial subject to Rule 16b-3 |
Koninklijke Philips Management Efficiency
The company has Return on Asset of 0.0136 % which means that on every $100 spent on assets, it made $0.0136 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0459) %, meaning that it generated no profit with money invested by stockholders. Koninklijke Philips' management efficiency ratios could be used to measure how well Koninklijke Philips manages its routine affairs as well as how well it operates its assets and liabilities. The Koninklijke Philips' current Return On Tangible Assets is estimated to increase to -0.03. The Koninklijke Philips' current Return On Capital Employed is estimated to increase to -0.0052. At this time, Koninklijke Philips' Total Current Assets are most likely to decrease significantly in the upcoming years. The Koninklijke Philips' current Intangible Assets is estimated to increase to about 3 B, while Non Currrent Assets Other are projected to decrease to roughly 2.8 B.Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| Bryan Hanson | Zimmer Biomet Holdings | 57 | |
| Omar Ishrak | Medtronic PLC | 63 | |
| Mark Tryniski | CONMED | 60 | |
| Norman Schwartz | Bio Rad Laboratories | 74 | |
| Bill Sanford | Integer Holdings Corp | 76 | |
| Curt Hartman | CONMED | 60 | |
| Roberto Quarta | Smith Nephew SNATS | 70 | |
| Michael Mahoney | Boston Scientific Corp | 59 | |
| Thomas Burns | Glaukos Corp | 63 | |
| Larry Glasscock | Zimmer Biomet Holdings | 71 | |
| Kevin Lobo | Stryker | 59 | |
| William Link | Glaukos Corp | 74 | |
| Marilyn Nelson | Inspire Medical Systems | 81 | |
| William Doyle | Novocure | 62 | |
| David Paul | Globus Medical | 57 | |
| Frank Laukien | Bruker | 64 | |
| Michael Mussallem | Edwards Lifesciences Corp | 71 | |
| Mohsen Sohi | STERIS plc | 61 | |
| Miles White | Abbott Laboratories | 65 | |
Management Performance
| Return On Equity | -0.0459 | ||||
| Return On Asset | 0.0136 |
Koninklijke Philips Leadership Team
Elected by the shareholders, the Koninklijke Philips' board of directors comprises two types of representatives: Koninklijke Philips inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Koninklijke. The board's role is to monitor Koninklijke Philips' management team and ensure that shareholders' interests are well served. Koninklijke Philips' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Koninklijke Philips' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Cascella, Executive Vice President, Strategic Business Development Leader | ||
| Willem Appelo, Chief Officer | ||
| Leandro Mazzoni, Head Relations | ||
| Neelam Dhawan, Independent Member of the Supervisory Board | ||
| Andy Ho, Executive Vice President, Chief Market Leader of Philips Greater China | ||
| Roy Jakobs, Executive Vice President Chief Business Leader - Personal Health | ||
| M Doherty, Independent Member of the Shariah Supervisory Board | ||
| Shez Partovi, Executive Vice President Chief Innovation and Strategy Officer | ||
| Bert Meurs, Executive Vice President, Chief Business Leader Image Guided Therapy and jointly responsible for Diagnosis & Treatment | ||
| Indra Nooyi, Independent Member of the Supervisory Board | ||
| Pim Preesman, Head of Investor Relations | ||
| Vitor Rocha, Executive Vice President, Chief Market Leader of Philips North America | ||
| Peter Loescher, Independent Member of the Supervisory Board | ||
| Sophie Bechu, Executive Vice President, Chief Operations Officer | ||
| Sock Chua, Independent Member of the Supervisory Board | ||
| Jeroen Veer, Independent Chairman of the Supervisory Board | ||
| Daniela Seabrook, Chief Human Resource Officer, Executive Vice President | ||
| Marnix Ginneken, Executive Vice President, Chief Legal & Compliance Officer, Member of the Management Board, Secretary | ||
| Christine Poon, Vice Chairman of the Supervisory Board, Secretary, Member of Corporate Governance, Nomination and Selection Committee and Member of Remuneration Committee | ||
| Henk Jong, Executive Vice President, Chief Executive Officer - Philips Domestic Appliances | ||
| A Harrison, Independent Member of the Supervisory Board | ||
| Kees Wesdorp, Executive Vice President Chief Business Leader Precision Diagnosis and jointly responsible for Diagnosis & Treatment | ||
| Orit Gadiesh, Independent Member of the Supervisory Board | ||
| Jeroen Tas, Executive Vice President Chief Innovation and Strategy Officer | ||
| Deeptha Khanna, Executive Vice President, Chief Business Leader of Personal Health | ||
| Heidi Sichien, Executive Officer | ||
| Paulus Stoffels, Independent Vice Chairman of the Supervisory Board, Secretary | ||
| Jan Kimpen, Chief Officer | ||
| Charlotte Hanneman, CFO VP | ||
| Franois Houten, Advisor | ||
| Francois Houten, President, Chief Executive Officer and Chairman of the Board of Management | ||
| Edwin Paalvast, Executive Vice President, Chief of International Markets | ||
| Sean Carney, Chief Officer | ||
| Feike Sijbesma, Independent Vice Chairman of the Supervisory Board | ||
| Abhijit Bhattacharya, Executive Vice President & Chief Financial Officer, Member of the Management Board | ||
| Carla Kriwet, Executive Vice President Chief Business Leader of Connected Care & Health Informatics (CCHI) Businesses | ||
| David Pyott, Independent Member of the Supervisory Board |
Koninklijke Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Koninklijke Philips a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0459 | ||||
| Return On Asset | 0.0136 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 31.41 B | ||||
| Shares Outstanding | 931.89 M | ||||
| Shares Owned By Institutions | 6.80 % | ||||
| Number Of Shares Shorted | 2.58 M | ||||
| Price To Earning | 33.57 X | ||||
| Price To Book | 1.95 X |
Currently Active Assets on Macroaxis
When determining whether Koninklijke Philips is a strong investment it is important to analyze Koninklijke Philips' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Koninklijke Philips' future performance. For an informed investment choice regarding Koninklijke Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Koninklijke Philips NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Koninklijke Philips. If investors know Koninklijke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Koninklijke Philips listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.069 | Earnings Share (0.51) | Revenue Per Share 19.75 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0136 |
The market value of Koninklijke Philips is measured differently than its book value, which is the value of Koninklijke that is recorded on the company's balance sheet. Investors also form their own opinion of Koninklijke Philips' value that differs from its market value or its book value, called intrinsic value, which is Koninklijke Philips' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Koninklijke Philips' market value can be influenced by many factors that don't directly affect Koninklijke Philips' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Koninklijke Philips' value and its price as these two are different measures arrived at by different means. Investors typically determine if Koninklijke Philips is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Koninklijke Philips' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.